Eli Lilly (NYSE:LLY) Surges 5% Following Breakthrough BRAVE-AA-PEDS Study Results
Recent developments at Eli Lilly (NYSE:LLY) have highlighted significant strides in both product innovation and operational ...
Nektar Q4 Loss Wider Than Expected, Pipeline in Focus, Stock Up
NKTR fourth-quarter earnings and revenues lag estimates. 2025 is poised to be a catalyst year for rezpeg, with multiple data readouts expected. Stock rises.
Model Portfolio For Capital Appreciation, March 2025
Discover 25 top investment-grade stocks to buy! See strategies to capitalize on market volatility and build a portfolio to ...
Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst
H.C. Wainwright & Co. initiates a Buy rating on Perspective Therapeutics, citing promising cancer radiotherapy assets.
Novo Nordisk rebounds as Kepler upgrades Ozempic maker at long last
Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read ...